STATUS: Planned

SPONSOR: AGO Study Group
LEAD GROUP: AGO
ENGOT Model: A
TITLE: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
ClinicalTrials.gov ID: NCT05009082

STATUS: Recruiting

SPONSOR: NOGGO
LEAD GROUP: NOGGO
ENGOT Model: B
TITLE: A Phase II randomized, open label, non-inferiority study of NiraParib maintenance after 3 vs. 6 cycles of platinum-based chemotherapy in completeLy debUlked advanced HRDpositive high-grade ovarian cancer patientS in first line therapy
ClinicalTrials.gov ID: NCT05460000
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: GINECO
LEAD GROUP: GINECO
ENGOT Model: A
TITLE: A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery
ClinicalTrials.gov ID:  NCT05183984
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: Daiichi Sankyo
LEAD GROUP: GINECO
ENGOT Model: C
TITLE: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
ClinicalTrials.gov ID: NCT06161025   
MaNGO Sites (click to see the list)

STATUS: Planned
SPONSOR: European Cancer Patient Coalition

LEAD GROUP: GINECO
ENGOT Model: A
TITLE: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery.”
ClinicalTrials.gov ID: NCT06476184
MaNGO Sites (click to see the list)

STATUS: Recruiting

SPONSOR: Verastem, Inc.
LEAD GROUP: NCRI
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
ClinicalTrials.gov ID: NCT06072781
MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Merck Sharp & Dohme LLC

LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of MK-2870 Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer
ClinicalTrials.gov ID: NCT06824467
MaNGO Sites(click to see the list)

STATUS: Recruiting

SPONSOR: Daiichi Sankyo, Inc.

LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer
ClinicalTrials.gov ID:  NCT06819007

STATUS: Planned

SPONSOR: Astrazeneca

LEAD GROUP: MaNGO
ENGOT Model: C
TITLE: Phase 3 study of AZD5335 vs. Mirvetuximab Soravtansine in FRα-High and AZD5335 vs. Investigator’s Choice Chemotherapy in FRα-Low Advanced High-Grade Platinum-Resistant Epithelial Ovarian Cancer (TREVI-OC-01)
ClinicalTrials.gov ID: NCT07044336

MaNGO Sites (click to see the list)

STATUS: Planned

SPONSOR: Eli Lilly and Company

LEAD GROUP:  GINECO/NOGGO
ENGOT Model: C
TITLE: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (FRAmework-01)
ClinicalTrials.gov ID:  NCT07213804

MaNGO Sites (will be available soon)